Patients reported satisfaction with nurse-led telephone end-of-treatment follow-up experiences; therefore, permanent modifications may be warranted. Read More ›

Breast cancer survival disparities persist even after adjusting for sociodemographic factors, tumor characteristics, and NCCN guideline–appropriate treatment, suggesting that social and environmental factors can impact survival. Read More ›

Interfacility variation in efforts to eliminate the use of unnecessary breast cancer procedures highlights the need for more formalized deimplementation plans. Read More ›

A diagnosis of breast cancer can cause stress and depression, especially in younger women. According to findings from a recent clinical trial, behavioral interventions may help decrease symptoms of depression and reduce anxiety, fatigue, and sleep disturbances in younger breast cancer survivors. Read More ›

Physicians often fail to perceive radiation-associated symptoms and the severity of those symptoms, according to the results of a large observational study that compared the reports of patients with breast cancer with physicians’ assessments of 4 common radiation-associated symptoms. Read More ›

Results of the SWOG S1007 RxPONDER clinical trial suggest that many postmenopausal women with early-stage hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative breast cancer, and 1 to 3 positive axillary lymph nodes may be able to avoid adjuvant chemotherapy. Read More ›

In the cancer care setting, telehealth was perceived favorably by patients and providers, providing a new pathway for accessing treatment in the future. Read More ›

The pandemic shifted patients’ fears, highlighting the critical importance of physician trust and language used in recruitment. Read More ›

The delivery of care transformed rapidly as healthcare systems innovated to handle the COVID-19 pandemic. The overarching goals and principles of cancer care did not change, but there was a heightened recognition of the challenges faced by cancer patients. Read More ›

The latest quality-of-life research from the MONALEESA-7 trial supports a strong clinical benefit-to-risk ratio with ribociclib-based treatment in pre- and perimenopausal patients. Read More ›